Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study.

Trial Profile

Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms FUTURE III
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 18 Feb 2010 New end-of-study per protocol efficacy analysis presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN 2010) conference, according to a Merck and Co media release.
    • 31 Aug 2009 Interim results were published in the Journal of Clinical Outcomes Management.
    • 14 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top